Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;26(6):609-11.
doi: 10.1089/aid.2009.0107.

Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine

Weerawat Manosuthi, David M Butler, Wasun Chantratita, Chonlaphat Sukasem, Douglas D Richman, Davey M Smith

Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine

Weerawat Manosuthi et al. AIDS Res Hum Retroviruses. 2010 Jun.
No abstract available

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Frequency of etravirine-RAMs among 134 CRF01_AE sequences.
See this image and copyright information in PMC

References

    1. Hammer SM. Eron JJ., Jr Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555–570. - PubMed
    1. Vingerhoets J. Azijn H. Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol. 2005;79(20):12773–12782. - PMC - PubMed
    1. Lazzarin A. Campbell T. Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):39–48. - PubMed
    1. Madruga JV. Cahn P. Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):29–38. - PubMed
    1. Vingerhoets J. Peeters M. Azijn H, et al. An update on the list of NNRTI mutations associated with decreased virological response to etravirine: Multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther. 2008;13(Suppl 3):A26.